HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, Jan. 26, 2018 (HealthDay News) -- For patients with mild Alzheimer's disease, solanezumab administered every four weeks does not alter cognitive decline, according to a study published in the Jan. 25 issue of the New England Journal of Medicine.
Lawrence S. Honig, M.D., Ph.D., from Columbia University Medical Center in New York City, and colleagues conducted a double-blind, placebo-controlled trial involving patients with mild dementia due to Alzheimer's disease. A total of 2,129 patients were enrolled and randomized to receive solanezumab (400 mg; 1,057 patients) or placebo (1,072 patients) intravenously every four weeks for 76 weeks.
The researchers found that the mean change from baseline in the score on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale score was 6.65 and 7.44 in the solanezumab and placebo groups, respectively, with no significant difference between the groups at week 80 (difference, −0.8; 95 percent confidence interval, −1.73 to 0.14; P = 0.1). The change from baseline in the Mini-Mental State Examination score was −3.17 and −3.66 in the solanezumab and placebo groups, respectively.
"Solanezumab at a dose of 400 mg administered every four weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline," the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly, which funded the study.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 28, 2022